<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622435</url>
  </required_header>
  <id_info>
    <org_study_id>LT10070-001</org_study_id>
    <nct_id>NCT05622435</nct_id>
  </id_info>
  <brief_title>Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers</brief_title>
  <official_title>Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial investigation is to evaluate the tolerance of the T10070 on&#xD;
      healthy volunteers by clinical examination under ophthalmological control.&#xD;
&#xD;
      Participants will attend 2 visits (inclusion at day 0 and follow-up/final at D7/D9. After&#xD;
      inclusion, subjects will have to apply T10070 6 times a day during 7 to 9 days. The following&#xD;
      tasks will be asked to participants:&#xD;
&#xD;
        -  ophtalmological examination&#xD;
&#xD;
        -  diary completion to record T10070 applications, potential discomfort/reactions observed&#xD;
           and medication taken.&#xD;
&#xD;
        -  complete subject questionnaire about usability of the product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2022</start_date>
  <completion_date type="Actual">November 10, 2022</completion_date>
  <primary_completion_date type="Actual">November 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in clinical examination on eyes and peri-ocular skin</measure>
    <time_frame>signs assessment at Day 0 and Day 7/Day 9</time_frame>
    <description>A clinical examination will be performed before and after product use on eyes and peri-ocular skin using 5-point structured scales (from &quot;Absence (0)&quot; to &quot;Severe (4)&quot;) to evaluate the intensity of several signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in subjective evaluation of ocular and cutaneous signs by subjects</measure>
    <time_frame>Signs assessment at Day 0 and Day 7/Day 9</time_frame>
    <description>A subjective tolerance evaluation will be performed before and after product use using 5-point structured scales (from &quot;No reaction (0)&quot; to &quot;Severe (4)&quot;).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerance assessed by Investigator</measure>
    <time_frame>Local tolerance assessed at Day 7/Day 9</time_frame>
    <description>Assessed using a 4-point scale (from &quot;Bad tolerance&quot; to &quot;Very good tolerance&quot;).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject questionnaire on product usability</measure>
    <time_frame>Day 7/Day 9</time_frame>
    <description>The subjective evaluation of the tested medical device will be assessed by subject by answering a satisfaction questionnaire. For each question, there are 4 possible answers (agree, somewhat agree, somewhat disagree, disagree)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 7/Day 9</time_frame>
    <description>Proportion of subjects experiencing at least one AE/SAE, TEAE related to the device, Serious TEAE.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>T10070</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T10070, Plastic tube with a roll-on applicator filled with an ointment</intervention_name>
    <description>6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.</description>
    <arm_group_label>T10070</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated&#xD;
&#xD;
          -  Subject ≥ 18 years old&#xD;
&#xD;
          -  Healthy volunteer&#xD;
&#xD;
          -  Normal ocular examination in both eyes&#xD;
&#xD;
          -  Normal skin examination in both eyes&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Far best-corrected visual acuity (BCVA) ≥ +0.1 LogMar (e.g., ≤ 0.8 in decimal value or&#xD;
             ≤ 80/100 Snellen equivalent)&#xD;
&#xD;
          -  Known or suspected hypersensitivity to one of the components of the T10070&#xD;
&#xD;
          -  History of trauma, infection, clinically significant inflammation within the 3&#xD;
             previous months&#xD;
&#xD;
          -  Ongoing or know history of ocular allergy and/or uveitis and/or viral infection&#xD;
&#xD;
          -  Diagnosed keratoconus&#xD;
&#xD;
          -  Any palpebral abnormality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewa Paw, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurofins Dermscan Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Dermscan Poland</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-288</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>October 12, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>December 6, 2022</last_update_submitted>
  <last_update_submitted_qc>December 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

